The ratios of FoxP3+ and CD45RO+ cells over the CD3+ cells in the tumor area as well as the ratios of FoxP3+ over the CD45RO+ cells in the tumor area were significantly associated with clinical outcomes. This evidence concerns the gene FOXP3 and neoplasm.